June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Interaction studies of RX-10045 (Resolvin E1 Analog) with Efflux TransportersInteraction studies of RX-10045 (Resolvin E1 Analog) with Efflux Transporters
Author Affiliations & Notes
  • Kishore Cholkar
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Hoang Trinh
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Aswanidutt Vadlapudi
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Zhiying Wang
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Dhananjay Pal
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Ashim K Mitra
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Footnotes
    Commercial Relationships Kishore Cholkar, None; Hoang Trinh, None; Aswanidutt Vadlapudi, None; Zhiying Wang, None; Dhananjay Pal, None; Ashim Mitra, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1197. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kishore Cholkar, Hoang Trinh, Aswanidutt Vadlapudi, Zhiying Wang, Dhananjay Pal, Ashim K Mitra; Interaction studies of RX-10045 (Resolvin E1 Analog) with Efflux TransportersInteraction studies of RX-10045 (Resolvin E1 Analog) with Efflux Transporters. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1197. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Resolvin E1 analog (RX-10045) was originally formulated as an aqueous solution and tested for the treatment of dry eye with topical drop application. RX-10045 was highly efficacious in murine models of dry eye syndrome. However, in Phase II clinical trials,RX-10045, though safe and well tolerated, produced equivocal efficacy results. Disposition across the human cornea and conjunctiva may be limited due to efflux transporters expressed on the ocular surface. Therefore, we aimed to screen interactions of RX-10045 with efflux transporters (P-gp, MRP2 and BCRP).

 
Methods
 

Madin-Darby canine kidney cells transfected with P-gp, MRP2 and BCRP gene were selected for this study. [3H]Digoxin, [3H]Vinblastine and [3H]Abacavir were selected as model substrates for P-gp, MRP2 and BCRP. Uptake and permeability studies in both apical to basal (AP−BL) and BL−AP of these substrates were conducted in presence of specific efflux pump inhibitors and RX-10045. Cell viability studies were conducted with increasing concentrations of RX-10045.

 
Results
 

Uptake studies showed higher accumulation in the presence of inhibitors (GF120918 and ketoconazole for P-gp; MK571 for MRP2 and β-estradiol for BCRP) as well as RX-10045. Similarly, dose dependent inhibition studies demonstrated higher accumulation of various substrates ([3H]-Digoxin, [3H]-Vinblastine and [3H]-Abacavir) in the presence of RX-10045. IC50 values of dose dependent inhibition of RX-10045 for P-gp, MRP2 and BCRP were 239 ±11.2 µM, 291 ± 79.2 µM and 300 ± 42 µM, respectively. Cell viability assay indicated no apparent toxicity at 350 µM concentration. Enhanced permeability for model substrates was observed in presence of RX-10045. Uptake studies in HCEC cells suggest RX-10045 is a strong inhibitor of organic cationic transporter-1 (OCT-1).

 
Conclusions
 

In summary, the resolvin analog (RX-10045) was identified as substrate/inhibitor for efflux transporters. Also, RX-10045 appears to be a strong inhibitor of OCT-1. Novel formulation strategies such as nanoparticles, nanomicelles and liposomes for circumventing efflux barriers and deliver higher drug concentrations leading to higher therapeutic efficacy may be employed.  

 
Fig 1. Apical to basal apparent permeability of [3H] vinblastine (MRP2 substrate) in the presence of inhibitor (MK571) and RX-10045 with [3H] vinblastine as control.
 
Fig 1. Apical to basal apparent permeability of [3H] vinblastine (MRP2 substrate) in the presence of inhibitor (MK571) and RX-10045 with [3H] vinblastine as control.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×